Feb 5 (Reuters) - VistaGen Therapeutics Inc VTGN.O:
VISTAGEN RECEIVES U.S. PATENT FOR AV-101 TO TREAT NEUROPATHIC PAIN
VISTAGEN THERAPEUTICS-PLANS TO SEEK POTENTIAL STRATEGIC COLLABORATIONS TO FURTHER ADVANCE POTENTIAL CLINICAL DEVELOPMENT, COMMERCIALIZATION OF AV-101
VISTAGEN THERAPEUTICS INC - PATENT WILL NOT EXPIRE UNTIL AT LEAST 2034
Source text: ID:nBw3rMzwHa
Further company coverage: VTGN.O